merck p53 peptide vaccine patent peptides - merrick-peptides p53 Merck's p53 Peptide Vaccine Patent: A Deep Dive into Cancer Therapy Innovation

merrifield-solid-phase-peptide-synthesis-ppt The pursuit of effective cancer treatments has long been a central focus for pharmaceutical giants like Merck1395TiP A randomized phase III trial .... A significant area of investigation involves the p53 protein, a critical tumor suppressor, and its potential role in therapeutic vaccines2017年3月31日—Peptideswere synthesized by solid phasepeptidesynthe- reportedvaccineplatform is advantageous compared to sis by methods known in the .... This exploration delves into the Merck p53 peptide vaccine patent landscape, examining how Merck and other entities have sought to leverage peptides derived from or targeting p53 to combat various cancers.Patents Assigned to Merck Sharp & Dohme Corp.

The p53 protein, often referred to as the "guardian of the genome," plays a vital role in preventing uncontrolled cell proliferation. When p53 is mutated or inactivated, it can significantly contribute to cancer development.Peptide vaccine formulations and use thereof for inducing an ... Consequently, researchers have explored strategies to restore or harness the power of p53 function. One such strategy involves developing p53 peptide vaccinesThe compound made by the process of the invention is an inhibitor of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and is therefore useful to treat .... These vaccines aim to stimulate the immune system to recognize and attack cancer cells that express or are affected by p53 abnormalitiesEP004029494A1* - EP 4 029 494 A1.

Merck's involvement in this field is evident through various patent filings.Monoclonal Antibodies against Specific p53 Hotspot ... For instance, U.S. Patent No. 8,663,646 B2, titled "P53 peptide vaccine," describes an invention related to a peptide derived from p53 that could serve as a vaccine against cancer. This aligns with the broader concept of peptide vaccines where specific fragments of disease-associated proteins are used to elicit an immune response. Another relevant patent, U.S. Patent No.作者：PL Bereano·1994—...p53- SCA Proteins - Schering-Plough - Somatix - 3TC - University of California - University of Michigan -Vaccines: A Round-Up of RecentPatentsand Allowances. 9,527,896 B2, titled "Stabilized p53 peptides and uses thereof," further indicates a focus on developing and stabilizing the p53 peptides for therapeutic applications, presumably within vaccine formulations.Abstract: The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor.

Beyond direct p53 vaccination, research has also focused on targeting proteins that regulate p53, such as HDM2 (Human Double Minute 2) and MDMX. By inhibiting these regulators, the activity of p53 can be enhanced.p53 Genetic Vaccine(NCI) - Drug Targets, Indications, ... This approach is reflected in patents like "P53 activator peptidomimetic macrocycles" and "Targeted MDM2 Degradation." These peptide mimetics and degradation strategies aim to indirectly bolster p53's tumor-suppressing capabilities, offering another avenue for cancer treatment. The patent landscape also shows a keen interest in inhibiting E3 ubiquitin ligase MDM2/MDMX, which are known to inhibit p53's tumor suppressor function, thus allowing for accelerated mutation-driven cancer progression.

The development of p53-based vaccines is not exclusive to Merck. The patent literature reveals a broader scientific effort. For example, WO 2006/124700, titled "P53 Vaccines for the Treatment of Cancers," highlights the global interest in this therapeutic areaPatent Landscape of DNA VACCINES FOR HIV. Additionally, mutant p53 has become a focus for some research, as seen in the "Mutant p53 peptide pulsed dendritic cell vaccine" concept, suggesting a strategy to target specific, altered forms of the p53 proteinDimeric Benzodiazepines as Peptide Mimetics to .... Research into targeting a neoantigen derived from a common TP53 mutation further underscores this direction.Product patents

The versatility of peptide technology extends to various vaccine platforms. The development of mRNA vaccines, as mentioned in U.The invention relates to concatemericpeptideepitope RNAs, as well as methods and compositions thereof. mRNAvaccinesare also provided according to the ...S.The compound made by the process of the invention is an inhibitor of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and is therefore useful to treat ... 2019/0008938 A1 ("Concatemeric peptide epitope rnas"), demonstrates how peptide sequences can be incorporated into novel delivery systems2004年11月17日—The followingpatentapplications are taken from the weekly EuropeanPatentsBulletin and give the publication number and date of .... Furthermore, peptide vaccines targeting tumor-associated antigens, including P53, are being explored in clinical trials, such as the randomized phase III trial referencing peptides restricted to HLA-A2 phenotype targeting tumor-associated antigens like P53.

While the p53 genetic vaccine initially developed by the National Cancer Institute has seen its research status as discontinued, the underlying principles of stimulating an immune response against p53-related mechanisms continue to drive innovation. The Merck p53 peptide vaccine patent portfolio, alongside numerous other patents and research initiatives, underscores the enduring scientific and commercial interest in unlocking the therapeutic potential of p53 and peptide vaccine strategies for improved cancer treatment. The ongoing exploration of peptide inhibitors, peptide mimetics, and various vaccine modalities signifies a dynamic field with the ultimate goal of developing more effective therapies against a wide spectrum of cancers.